It was a never-ending nightmare. Unfortunately, $SRT (+0,25 %) I sold at a significant loss. Luckily, I got some capital gains tax refund. Plus, I sold near the 52-week high—I wouldn’t have hoped for that much a few months ago. Not all deals work out every time.

$$SRT (+0,25 %) has recovered significantly and reached a new 52-week high today. Analysts’ median price target is €243

https://de.tradingview.com/symbols/XETR-SRT/forecast-price-target/

I took advantage of the rally and set a trailing stop-loss just below the high. I’d rather get out with a 35% loss than waste any more time with them for much longer and at a much lower price.

What do you think $SRT (+0,25 %) ? Do you have high hopes for the company, and do you still see potential in bioprocessing?

$SRT (+0,25 %) It's been sitting like a dead weight in my portfolio since February 2025. A friend recommended it to me back then, and I jumped in without doing much research of my own. Right now, I’m down about 45%.

Now I’ve read up a bit on the company and looked at the current and projected figures, and the projections in particular look good:

https://de.marketscreener.com/kurs/aktie/SARTORIUS-AG-436557/finanzen/

2025 marked the turnaround, and things are expected to pick up starting in 2026:

2025 2026 2027

Revenue 4.6% 6% 9.45%

EBITDA 11.28% 6.8% 12.69%

FCF -31% 13.4% 31.9%

To me, this looks like a good turnaround case, so I’m considering holding onto my position for now and waiting it out—or possibly buying more if necessary.

Of 20 analysts, 14 see a buy signal with an average price target of €266. That would be a nice boost.

What does the community think $SRT (+0,25 %) ? Should we steer clear of biopharma in Germany, or do you see a case here as well? Is it better to take the loss? Should we wait for the trend to turn or even add to our position?

As of July 1, 2026, 4:30 p.m.

Price: €188.90

Okay, today I’m going to do a little “shitposting” (or as a German would say: posting crap).

But you really have to realize just how bad things actually are for the German stock market. I now truly consider it my biggest rookie mistake as an individual stock investor that I ever bought into this nonsense about “global diversification” and “spreading your investments widely.”

There are simply countries that, on average, are uninvestable—and unfortunately, in addition to various emerging markets, this increasingly includes some European nations as well.

And this is actually a structural issue. Topics like “small caps” and “hidden champions” can basically be flushed down the toilet at this point, because policymakers are… let’s just say… creating suboptimal economic conditions in Europe.

What we’re seeing here isn’t solely due to poor stock picking, but is also indicative of just how badly the German stock market as a whole is faring. Take a look at the index ETF $DEAM (+0,13 %) and see that the MDAX (which, after all, still forms the backbone of the German economy) has shown absolutely no return over the past five years.

Does anyone else remember how, a few years ago, people kept saying that while Germany might not have any great global IT corporations, the German SME sector—with its technology leaders and highly specialized niche providers—would pull everything through? What’s left of that? Not a chance! Whether $RAA (-1,56 %) or $NEM (+3,64 %) or $AFX (-1,86 %) or $SRT (+0,25 %) or $BC8 (-0,67 %) —many of Germany’s rising stars, especially in future-oriented markets, have failed—all at the same time. Let’s not even get started on BioNTech this time.

Meanwhile, the DAX is increasingly becoming a “retirees’ club” of companies, some of which are 100 to 150 years old and are filling the index with their spin-offs. For example, $FRE (+1 %) Fresenius is represented twice, $MBG (+1,05 %) Mercedes is represented twice, and $SIE (-0,32 %) Siemens is even represented four times. These three companies alone already occupy eight spots on the DAX, while success stories of a company rising from an SME to a major corporation—as in the case of Qiagen—are almost nonexistent anymore. And even with Qiagen, we’ll have to wait and see whether the company can hold its own in the “top league” in the long run.

To be honest, the fact that the DAX is still doing relatively well at all is due solely to the success of a few companies and their economies of scale, which allow them to engage in lobbying at both the federal and European levels. However, the weaker Germany becomes, the less likely it will be in the long run for finance ministers to use their leeway to benefit large corporations or for foreign ministers to advocate for international trade agreements.

Unfortunately, things don’t look much better in the rest of Europe either. Here, however, the economy doesn’t have as much room to fall in the first place. Many European countries have never defined themselves as “economic nations” anyway, but rather see themselves as cultural nations. But even here, one can take a look at what has become of the jewels of the European stock markets. Europe’s top 10 is now dominated by British and Swiss companies, while the heavyweights from Germany and France continue to lose ground. Yes, Siemens is holding its own, but Germany’s flagship industry used to be automotive manufacturing. And the only 5-star company in the EU is ASML.

I’ve now written much more than I intended for a lighthearted post, and I’m not even sure anymore what point I was trying to make.

I don’t know—just don’t buy so many dubious individual stocks from shady countries just because you want to diversify. Buy only the best stocks, and if you can’t think of any others, just put the rest into the S&P 500.

$DIS (+1,65 %)
$PLTR (+0,52 %)
$SRT (+0,25 %)
$NXPI (-0,39 %)
$PYPL (+2,9 %)
$PEP (-0,05 %)
$TER (-0,47 %)
$CPRI (+0,86 %)
$MRK (-2,69 %)
$PFE (-0,99 %)
$TTWO (+0,47 %)
$EA
$AMD (+0,11 %)
$MDLZ (+0,58 %)
$LUMN (-1,27 %)
$SMCI (-0,67 %)
$7011 (-0,01 %)
$6752 (+2,14 %)
$6367 (-0,88 %)
$UBSG (+1,31 %)
$GSK (-0,36 %)
$UBER (+2,3 %)
$ABBV (+1,43 %)
$LLY (+0,46 %)
$GOOG (+1,38 %)
$ELF (-0,03 %)
$QCOM (-1,7 %)
$SNAP (+0,65 %)
$WOLF (-4,57 %)
$ARM (-1,1 %)
$VOLCAR B (+0 %)
$6758 (-1,08 %)
$SHL (-1,06 %)
$SAAB B (+1,5 %)
$5401 (-0,43 %)
$MAERSK A (-0,96 %)
$R3NK (+0,3 %)
$BMY (-3,68 %)
$BMW (+0,07 %)
$EL (+1,71 %)
$ROK (+0,67 %)
$PTON (+1,6 %)
$KKR (-0,1 %)
$LIN (+1,13 %)
$RL (+0,99 %)
$AGCO (+1,82 %)
$RBLX (+1,79 %)
$FTNT (+2,42 %)
$REDDIT
$ILMN (+8,06 %)
$WMG (+3,29 %)
$IREN (-2,87 %)
$MSTR (+2,76 %)
$AMZN (+0,57 %)
$KOG (+0,81 %)
$ORSTED (-4,15 %)
$PM (+1,38 %)
$WEED (+1,03 %)

What do you think of $SRT (+0,25 %) ? Analysts see an average of €245, which would mean considerable potential. The company is currently hiring again and the management considers the trough to be over. The last figures were optimistic.

Is an entry around 210€ worthwhile?

!Preference shares $SRT3 (+0,14 %) are at 260 and are not common!

#rtw

$ERIC A (-0,18 %)
$DPZ (+0 %)
$JNJ (-0,88 %)
$JPM (+0,25 %)
$WFC (+1,87 %)
$BLK (+0,93 %)
$GS (-0,61 %)
$C (+0,25 %)
$MC (+0,79 %)
$ASML (+0,08 %)
$BAC (+0,81 %)
$MS (+0,27 %)
$JBHT (-0,65 %)
$EQT (+2,09 %)
$SRT (+0,25 %)
$NESNE
$TSM (+2,85 %)
$ABBN (+0,18 %)
$UAL (-1,6 %)
$TOM (+1 %)
$VOLV B (-0,55 %)
$AXP (+0,95 %)
$SLBG34
$STT (+0,59 %)

How do you deal with losses? Do you realize them promptly or do you wait and see?

I mostly invest for the long term. At least until I found this portal here 😇

I actually buy stocks that I'm convinced of and then leave them. Always with money that I don't need elsewhere.

Now, for example, I have titles like $EVT (+1,19 %)
$SRT (+0,25 %) or $S92 (-2,57 %) . All deep red. Wouldn't really bother me, I don't need the money. I have enough cash to buy other stocks.

Is it still worth selling because of taxes or how do you handle such cases?

What are your portfolio corpses?

$SRT (+0,25 %)

Sartorius sees itself on track after a solid Q2 2025 and confirms the forecast for the full year.

📈 H1 figures at a glance:

▪️ Sales revenue: +6.1% to €1.77 billion

▪️ Adjusted EBITDA: € 527 million

▪️ Bioprocess Solutions division: +8.8%

🎯 Forecast 2025 confirmed:

▪️ Organic sales growth ~6%

▪️ Operating EBITDA margin: 29-30%

🔎 Despite global uncertainties, Sartorius remains confident.

$XDWH (+0,95 %)
$XLV (+1,06 %)
$CSPX (+1,06 %)
$VUSA (+1,05 %)
$UNH (+1,94 %)
$OSCR (+5,72 %)

According to Goldman Sachs, healthcare is the only sector in the S& P 500 that is cheaper than the 10- and 30-year averages.

This is an extremely attractive risk/reward ratio and the coming months will be exciting.

$ELV (+2,76 %)
$CNC (+2,36 %)
$DHR (+3,77 %)
$SRT (+0,25 %)
$LLY (+0,46 %)
$NOVO B (+1 %)
$NVO (+1,15 %)
$ISRG (+4,2 %)
$JNJ (-0,88 %)
$ABBV (+1,43 %)
$PFE (-0,99 %)
$SAN (-0,8 %)
$MRK (-2,69 %)
$BMY (-3,68 %)
$TMO (+3,57 %)